ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The third-generation tyrosine kinase inhibitor DCC-2036 (Rebastinib), designed as an inhibitor of ABL1 switch-control, is powerful in chronic myeloid leukemia (CML).